Crescent Biopharma (CBIO) earnings

Healthcare · Biotechnology · Market cap $419M

In the quarter ended June 2026, Crescent Biopharma had revenue of $0.

On July 30, 2026 it reported EPS of -0.74 against an estimate of -0.78 (beat).

The next report is expected on Thursday, November 5, 2026, with EPS expected around -0.72.

Report dates

ReportDateTimeEPS estimateEPS reported
NextThu Nov 5, 2026 — -0.72 —
LastThu Jul 30, 2026 — -0.78 -0.74

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 12 quarters from Crescent Biopharma's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2026$0 — — — — 2026-07-30
Mar 31, 2026$1M — — — -2380.1% 2026-04-29
Dec 31, 2025— — — — — 2026-02-26
Sep 30, 2025— — — — — 2025-11-06
Jun 30, 2025$0 — — — — 2025-07-31
Mar 31, 2025$0 — -0.04 — — 2025-05-14
Dec 31, 2024— — — — — 2025-02-13
Sep 30, 2024— — -0.15 — — 2024-11-13
Jun 30, 2024— — -0.16 — — 2024-08-08
Mar 31, 2024— — -0.04 — — 2024-05-09
Dec 31, 2023— — — — — 2024-03-27
Sep 30, 2023— — -0.14 — — 2023-11-03
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CBIO.
Open CBIO in Investingly

Questions

When does Crescent Biopharma report earnings?

Crescent Biopharma's next earnings report is expected on November 5, 2026.

How did Crescent Biopharma do last quarter?

In the quarter ended June 2026, Crescent Biopharma had revenue of $0.

From Crescent Biopharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.